[go: up one dir, main page]

CA2386064A1 - Recepteur associe a l'oestrogene, err alpha, regulateur de la formation osseuse - Google Patents

Recepteur associe a l'oestrogene, err alpha, regulateur de la formation osseuse Download PDF

Info

Publication number
CA2386064A1
CA2386064A1 CA002386064A CA2386064A CA2386064A1 CA 2386064 A1 CA2386064 A1 CA 2386064A1 CA 002386064 A CA002386064 A CA 002386064A CA 2386064 A CA2386064 A CA 2386064A CA 2386064 A1 CA2386064 A1 CA 2386064A1
Authority
CA
Canada
Prior art keywords
alpha
err
erra
protein
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002386064A
Other languages
English (en)
Inventor
Jane E. Aubin
Edith Bonnelye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002284103A external-priority patent/CA2284103A1/fr
Application filed by Individual filed Critical Individual
Priority to CA002386064A priority Critical patent/CA2386064A1/fr
Publication of CA2386064A1 publication Critical patent/CA2386064A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2857—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, orphan receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Méthodes et compositions pharmaceutiques pour la modulation de la formation osseuse chez un mammifère. Des méthodes d'analyse de l'efficacité de composés en tant que modulateurs de la formation osseuse sont également décrites.
CA002386064A 1999-09-30 2000-08-30 Recepteur associe a l'oestrogene, err alpha, regulateur de la formation osseuse Abandoned CA2386064A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002386064A CA2386064A1 (fr) 1999-09-30 2000-08-30 Recepteur associe a l'oestrogene, err alpha, regulateur de la formation osseuse

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002284103A CA2284103A1 (fr) 1999-09-30 1999-09-30 Recepteur des oestrogenes, err.alpha, un regulateur de la formation osseuse
CA2,284,103 1999-09-30
CA002386064A CA2386064A1 (fr) 1999-09-30 2000-08-30 Recepteur associe a l'oestrogene, err alpha, regulateur de la formation osseuse
PCT/CA2000/001015 WO2001022988A1 (fr) 1999-09-30 2000-08-30 Recepteur associe a l'oestrogene, err alpha, regulateur de la formation osseuse

Publications (1)

Publication Number Publication Date
CA2386064A1 true CA2386064A1 (fr) 2001-04-05

Family

ID=25681224

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002386064A Abandoned CA2386064A1 (fr) 1999-09-30 2000-08-30 Recepteur associe a l'oestrogene, err alpha, regulateur de la formation osseuse

Country Status (1)

Country Link
CA (1) CA2386064A1 (fr)

Similar Documents

Publication Publication Date Title
Mackie et al. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line
Bord et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts
Bonnelye et al. The orphan nuclear estrogen receptor–related receptor α (Errα) is expressed throughout osteoblast differentiation and regulates bone formation in vitro
Van Der Eerden et al. Expression of Indian hedgehog, parathyroid hormone‐related protein, and their receptors in the postnatal growth plate of the rat: evidence for a locally acting growth restraining feedback loop after birth
He et al. Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor‐β type II receptor family
Saidak et al. Extracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor
US20100119505A1 (en) Estrogen Related Receptor, ERRalpha, A Regulator of Bone Formation
Conover et al. The role of insulin-like growth factors and binding proteins in bone cell biology
EP2548579B1 (fr) Cibler la régulation du VEGF-B des transporteurs d'acides gras afin de moduler les maladies humaines
Kamiya et al. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength
JP2002526109A (ja) アポトーシス誘導物質と方法
JP2010532360A (ja) 骨障害の処置における使用のためのａｘｌのモジュレーター
Appelman-Dijkstra et al. Novel approaches to the treatment of osteoporosis
Hollnagel et al. Parathyroid Hormone Enhances Early and Suppresses Late Stages of Osteogenic and Chondrogenic Development in a BMP‐Dependent Mesenchymal Differentiation System (C3H10T½)
Gooi et al. Decline in calcitonin receptor expression in osteocytes with age
Shin et al. N-formyl-methionyl-leucyl-phenylalanine (fMLP) promotes osteoblast differentiation via the N-formyl peptide receptor 1-mediated signaling pathway in human mesenchymal stem cells from bone marrow
JP2003512304A (ja) 医薬組成物および分泌フリズル化関連タンパクを用いる方法
CA2267666A1 (fr) Nouveau transducteur de signaux repondant aux elements morphogenes et procedes d'utilisation
Kremer et al. Parathyroid hormone related protein (PTHrP) in tumor progression
Adams et al. Identification of a novel parathyroid hormone-responsive gene in human osteoblastic cells
US20020187953A1 (en) Estrogen receptor-related receptor alpha (ERRalpha) and cartilage formation
US8399421B2 (en) Treatment for neuropathic pain due to spinal cord injury
Kim et al. Stanniocalcin 1 and 1, 25-dihydroxyvitamin D3 cooperatively regulate bone mineralization by osteoblasts
CA2386064A1 (fr) Recepteur associe a l'oestrogene, err alpha, regulateur de la formation osseuse
JP2004507259A (ja) 骨生成の変調及び脂質生成の阻害をする物質の使用方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead